Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-κB pathway as a target for new therapeutic strategies

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J. Lymphoma classification – from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 2000; 11: 3–10
   PubMed Web of Science ®Google Scholar
• Pileri S A, Dirnhofer S, Went P, Ascani S, Sabattini E, Marafioti T, et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002; 41: 482–509
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der L H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003; 88: 1304–1315
   PubMed Web of Science ®Google Scholar
• Sweetenham J W. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Progr 2005; 252–259
   PubMedGoogle Scholar
• Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani P L, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54–58
   PubMed Web of Science ®Google Scholar
• Krishnan A, Nademanee A, Fung H C, Raubitschek A A, Molina A, Yamauchi D, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 90–95
   PubMed Web of Science ®Google Scholar
• Shipp M, Harrington D, Anderson JR, Armitage J, Banadonna G, Britlinger G, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Sehn L H, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861
   PubMed Web of Science ®Google Scholar
• Ngo L, Hee S W, Lim L C, Tao M, Quek R, Yap S P, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008; 49: 462–469
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis Re, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 20(346)1937–1947
   Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 15(198)851–862
   Web of Science ®Google Scholar
• Nyman H, Adde M, Karjalainen-Lindsberg M L, Taskinen M, Berglund M, Amini R M, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930–4935
   PubMed Web of Science ®Google Scholar
• Lossos I S, Alizadeh A A, Eisen M B, Chan W C, Brown P O, Botstein D, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000; 97: 10209–10213
   PubMed Web of Science ®Google Scholar
• Iqbal J, Sanger W G, Horsman D E, Rosenwald A, Pickering D L, Dave B, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004; 165: 159–166
   PubMed Web of Science ®Google Scholar
• Iqbal J, Neppalli V T, Wright G, Dave B J, Horsman D E, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961–968
   PubMed Web of Science ®Google Scholar
• Mittrucker H W, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997; 275: 540–543
   PubMed Web of Science ®Google Scholar
• Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000; 14: 449–456
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula S V, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006; 20: 311–317
   Web of Science ®Google Scholar
• Tam W, Gomez M, Chadburn A, Lee J W, Chan W C, Knowles D M. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107: 4090–4100
   PubMed Web of Science ®Google Scholar
• Liu Y Y, Leboeuf C, Shi J Y, Li J M, Wang L, Shen Y, et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood 2007; 110: 339–344
   PubMed Web of Science ®Google Scholar
• Davis R E, Brown K D, Siebenlist U, Staudt L M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 17: 1861–1874
   Web of Science ®Google Scholar
• Rodig S J, Savage K J, LaCasce A S, Weng A P, Harris N L, Shipp M A, et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 2007; 31: 106–112
   PubMed Web of Science ®Google Scholar
• Feuerhake F, Kutok J L, Monti S, Chen W, LaCasce A S, Cattoretti G, et al. NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392–1399
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classixfication of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Amen F, Horncastle D, Elderfield K, Banham A H, Bower M, Macdonald D, et al. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. Histopathology 2007; 51: 70–79
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Farinha P, Hsi E D, Hans C P, Tibshirani R, Sehn L H, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008; 26: 447–454
   PubMed Web of Science ®Google Scholar
• Roberts R A, Wright G, Rosenwald A R, Jaramillo M A, Grogan T M, Miller T P, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006; 108: 311–318
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger D D, Choi W W, Perry K D, Smith L M, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008, [Epub ahead of print]
   Google Scholar
• Rimsza L M, Leblanc M L, Unger J M, Miller T P, Grogan T M, Persky D O, et al. Gene expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma treated with R-CHOP. Blood 2008, [Epub ahead of print]
   Google Scholar
• Mounier N, Briere J, Gisselbrecht C, Emile J F, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284
   PubMed Web of Science ®Google Scholar
• Brock N. The history of the oxazaphosphorine cytostatics. Cancer 1996; 78: 542–547
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229
   PubMed Web of Science ®Google Scholar
• Johnson I S, Armstrong J G, Gorman M, Burnett J P, Jr. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963; 23: 1390–1427
   PubMed Web of Science ®Google Scholar
• Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297–309
   PubMed Web of Science ®Google Scholar
• Karin M, Cao Y, Greten F R, Li Z W. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301–310
   PubMed Web of Science ®Google Scholar
• Bottero V, Busuttil V, Loubat A, Magné N, Fischel J L, Milano G, et al. Activation of nuclear factor κB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001; 61: 7785–7791
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, Hurt E H, Wiestner A, Staudt L M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991–9996
   PubMed Web of Science ®Google Scholar
• Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84
   PubMed Web of Science ®Google Scholar
• Lam L T, Davis R E, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28–40
   PubMed Web of Science ®Google Scholar
• Lenz G, Davis R E, Ngo V N, Lam L, George T C, Wright G W, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676–1679
   PubMed Web of Science ®Google Scholar
• Jazirehi A R, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{κ}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65: 264–276
   PubMed Web of Science ®Google Scholar
• Richardson P G, Mitsiades C, Hideshima T, Anderson K C. Proteasome inhibition in the treatment of cancer. Cell Cycle 2005; 4: 290–296
   Google Scholar
• Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 2007; 29: 272–284
   PubMed Web of Science ®Google Scholar
• Cusack J C, Liu R, Houston M, Abendroth K, Elliott P J, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001; 61: 3535–3540
   PubMed Web of Science ®Google Scholar
• Jazirehi A R, Vega M I, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67: 1270–1281
   PubMed Web of Science ®Google Scholar
• Leonard J P, Furman R R, Cheung Y K, Vose J M, Glynn P W, Ruan J, et al. CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2007; S25: 8031
   Google Scholar
• Goy A, Younes A, McLaughlin P, Pro B, Romaguera J E, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
   PubMed Web of Science ®Google Scholar
• Bortezomib and Vorinostat in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma, National Cancer Institute (NCI). June, 2008
   Google Scholar
• Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G, et al. Down-regulating constitutive activation of the NF-κB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006; 107: 2354–2363
   PubMed Web of Science ®Google Scholar
• Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse M L, Fölsch U R, et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243–3251
   PubMed Web of Science ®Google Scholar
• Arlt A, Vorndamm J, Breitenbroich M, Fölsch U R, Kalthoff H, Schmidt W E, et al. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001; 20: 859–868
   PubMed Web of Science ®Google Scholar
• Scaife C L, Kuang J, Wills J C, Trowbridge D B, Gray P, Manning B M, et al. Nuclear factor κB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res 2002; 62: 6870–6878
   PubMed Web of Science ®Google Scholar
• Rundall B K, Denlinger C E, Jones D R. Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004; 136: 416–425
   PubMed Web of Science ®Google Scholar
• Dai Y, Pei X Y, Rahmani M, Conrad D H, Dent P, Grant S. Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 2004; 103: 2761–2770
   PubMed Web of Science ®Google Scholar
• Jüliger S, Goenaga-Infante H, Lister T A, Fitzgibbon J, Joel S P. Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-κB inhibition and the rapid generation of other selenium species. Cancer Res 2007; 167: 10984–10992
   Web of Science ®Google Scholar